Quarterly Update on Carbapenem-Resistant Enterobacteriaceae and Other Carbapenemase-Producing Organisms for Washington State

ISOLATES REPORTED TO THE DEPARTMENT OF HEALTH AND TESTED AT THE PUBLIC HEALTH LABORATORIES, BY DATE OF COLLECTION, JANUARY - MARCH 2019

This update summarizes reports of carbapenem-resistant Enterobacteriaceae (CRE) isolates and other carbapenemase-producing organisms (CPO) from January through March, 2019. CRE and other CPO isolates are counted from any person diagnosed in-state or from Washington residents diagnosed out-of-state and reported to the department. Since surveillance began in 2012, only the first unique genus/species/carbapenemase profile from each patient is counted. Isolates producing more than one carbapenemase are counted once for each novel carbapenemase.

CRE
The CRE case definition since May 2015, is:
*E. coli*, *Klebsiella* spp., and *Enterobacter* spp. resistant to any carbapenem, according to Clinical Laboratory Standards Institute (CLSI) breakpoints: minimum inhibitory concentrations of ≥4 mcg/ml for meropenem, imipenem, and doripenem or ≥ 2 mcg/ml for ertapenem.


Testing performed at PHL on CRE includes confirmation of identification and antibiotic sensitivity (AST), a phenotypic test to detect carbapenemase activity using the Modified Carbapenem Inactivation Method (mCIM), and PCR for the following five common carbapenemase genes:

- *Klebsiella pneumoniae* carbapenemase (KPC)
- New Delhi metallo-β-lactamase (NDM)
- Oxacillin-hydrolyzing β-lactamase-48 (OXA-48)
- Verona integron-encoded metallo-β-lactamase (VIM)
- Imipenem-hydrolyzing β-lactamase (IMP)

Any CRE isolate that is positive by mCIM test but negative by PCR for the five carbapenemase genes is suspicious for novel carbapenemase and these isolates are submitted to Centers for Disease Control and Prevention for further testing. PHL can test other CR-genera within the family Enterobacteriaceae by special request, or through a sentinel surveillance agreement.

Other CPO
PHL solicits and tests other Gram-negative organisms. CR-*Pseudomonas* isolates are submitted by 22 sentinel laboratories in Washington. The department requests that CR-*Acinetobacter* isolates be submitted by all laboratories in the state. Carbapenem-resistance in other genera of bacteria is determined by CLSI breakpoints.

PHL began testing CR-*Acinetobacter* isolates with the following carbapenemase targets in March 2019:

- Oxacillin-hydrolyzing β-lactamase-23 like (OXA-23)
- Oxacillin-hydrolyzing β-lactamase-24/40 like (OXA-24/40)
- Oxacillin-hydrolyzing β-lactamase-58 like (OXA-58)
The bar graph shows CRE and carbapenemase-producing Enterobacteriaceae isolates collected in 2019, compared to those submitted and tested in 2018 (Figure 1).

**Figure 1. Carbapenem-Resistant Enterobacteriaceae Isolates, Washington, 2018 and 2019**

**Quarter 1 2019**

**CRE surveillance:**

- Sixty-one (61) CRE isolates were reported statewide in the first quarter of 2019. The contrasting color/pattern at the top of each bar represents the number of CRE isolates that were confirmed by PCR testing to carry a carbapenemase gene (Figure 1).
- Of 61 CRE isolates, 53 (87%) were “big-three” genera isolates that are required to be reported: 28 (46%) *Enterobacter* spp., 15 (25%) *E. coli*, and 10 (16%) *Klebsiella* spp. Other Enterobacteriaceae genera submitted and tested were: 2 (3%) *Morganella* spp., 4 (7%) *Serratia* spp., and 2 (3%) *Proteus* spp. (Figure 2).
- Of 61 CRE isolates, 12 (22%) isolates from 11 individual patients tested positive for carbapenemase: 4 KPC, 2 OXA-48 like, 3 NDM, and 3 presumed or confirmed *Serratia marcescens* Enzyme (SME). (Figure 2)
- Four of 10 (40%) of *Klebsiella* isolates were carbapenemase-positive, as were 3 of 15 (20%) *E. coli* isolates and 2 of 28 (7%) *Enterobacter* isolates. (Figure 2)
- Of three *Serratia* isolates positive for carbapenemase activity by mCIM test, two were confirmed as SME through testing at CDC and the third was presumed SME based on having the SME resistance phenotype. SME is common in *Serratia* spp. and is usually located on a chromosome rather than on a plasmid. As such, isolates with SME carbapenemases are not targeted for public health investigation. (Figure 2)
- One *Klebsiella pneumoniae* isolate was positive for both OXA-48 and NDM, and therefore was counted twice, once for each carbapenemase.
- The likely source of acquisition for 4 of the 8 patients with CP-CRE was healthcare in Washington. The other 4 CP-CRE cases likely acquired the carbapenemase during international travel or healthcare. (The SME cases are not included.) (Table 1)
- We offer a breakdown of cases by county to inform local public health, facilities, and providers of recent carbapenemase activity in their region. The quarter 1 map of cases by county of residence or diagnosis (non-WA residents) is shown in Figure 3.

**CRPA/CRA surveillance:**

- Eighty-seven (87) CR-*Pseudomonas* and six (6) CR-*Acinetobacter* isolates were submitted for carbapenemase testing in the first quarter of 2019. (Figure 2)
- Two of 87 (2%) *Pseudomonas* isolates were positive for carbapenemase: 1 VIM and 1 unidentified carbapenemase (mCIM+).
- Three of 6 (50%) *Acinetobacter* isolates were positive for OXA-23 carbapenemase in quarter 1.
The Public Health Laboratories accepts and tests other carbapenem-resistant Gram-negative organisms, such as other genera in the family Enterobacteriaceae, upon request, or if specialized screening tests (e.g., Metallo-B-lactamase test, modified Hodge test (MHT) (for *E. coli* and *Klebsiella* species only), CarbaNP, Carbapenem Inactivation Method (CIM) or modified CIM (mCIM) indicate suspicion for carbapenemase production.

Please contact Kelly Kauber at 206-418-5500 or kelly.kauber@doh.wa.gov for any questions or comments about this report, or for information on becoming a sentinel lab.